Efavirenz in the therapy of HIV infection.
Efavirenz in the therapy of HIV infection.
复制标题
Efavirenz在HIV感染的治疗中。
DOI:
10.1517/17425250903483207
复制
发表时间:
2010-01
影响因子:
4.3
通讯作者:
van den Anker JN
中科院分区:
文献类型:
--
作者:
Rakhmanina NY;van den Anker JN
The use of the first generation non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) as a component of first-line antiretroviral therapy has been accepted worldwide. EFV is the only antiretroviral agent currently on the market that has been combined with emtricitabine and tenofovir disoproxil fumarate in a single tablet and administered once-daily. This article reviews efficacy and safety data on efavirenz and the role of pharmacogenetics in EFV exposure. Published articles and conference presentations on efavirenz are reviewed. CYP2B6 genetic polymorphisms influence the metabolism of EFV. The CYP2B6 G to T polymorphism at position 516 is have been shown to be associated with elevated plasma concentrations and an increase in neurotoxicity of EFV, while the wild-type genotype has been associated with sub-therapeutic concentrations of EFV, potentially leading to the development of viral resistance. This polymorphism is significantly higher in Sub-Saharan Africans and African Americans as compared to Hispanic, European and Asian populations. The significance of CYP2B6 polymorphism in EFV exposure indicates the need for prospective clinical studies to evaluate the utility of genotype-driven dose adjustments in populations of diverse descent.
登录
查看更多内容
DOI:
10.1080/13625180701829952
发表时间:
2008-06-01
影响因子:
1.7
作者:
El-Ibiary, Shareen Y.;Cocohoba, Jennifer M.
通讯作者:
Cocohoba, Jennifer M.
影响因子:
4.9
作者:
Cabrera, Salvador E.;Santos, Dolores;Garcia, Maria J.
通讯作者:
Garcia, Maria J.
影响因子:
2.6
作者:
di Iulio, Julia;Fayet, Aurelie;Telenti, Amalio
通讯作者:
Telenti, Amalio
影响因子:
158.5
作者:
Gulick, RM;Ribaudo, HJ;Kuritzkes, DR
通讯作者:
Kuritzkes, DR
影响因子:
11.8
作者:
Gatanaga, Hiroyuki;Hayashida, Tsunefusa;Oka, Shinichi
通讯作者:
Oka, Shinichi